Cynthia (Cindy) Collins, is a recognized leader in cell and gene therapy, genomic medicine, molecular diagnostics, life sciences, and therapeutics. Prior to her most recent position as CEO of Editas Medicine (Nasdaq:EDIT), she served as CEO of Human Longevity Inc, a genomics-based company.  Prior to Human Longevity Cindy served as CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics. Before GE, Cindy served as President and CEO of GenVec (Nasdaq:GNVC) and Group Vice President, Cellular Analysis Business of Beckman Coulter. Prior to Beckman Coulter, she served as President and CEO of Sequoia Pharmaceuticals. Earlier, Cindy served as President of Clinical Micro Sensors, Inc., a wholly-owned subsidiary of Motorola. Prior to Motorola, she spent 17 years with Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President & General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies. She began her career with Abbott Laboratories where she spent 6 years in various operating roles.  Cindy received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA, from The University of Chicago Booth School of Business. Cindy is a member of the board of directors of DermTech (Nasdaq:DMTK), Certara (Nasdaq:CERT), and Poseida Therapeutics (Nasdaq:PSTX).